Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

TAK-375 Takeda.

Christian Cajochen¹

¹Centre for Chronobiology, Psychiatric University Clinic, Basel, Switzerland. christian.cajochen@pukbasel.ch

Current Opinion in Investigational Drugs (London, England : 2000)

|January 29, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Who Blames the Moon for Poor Sleep? An Exploratory Online Survey.

Clocks & sleep·2026

Same author

Chronotype and Time of Day Effects in Oddball Task Performance: Behavioural and Cerebral Correlates.

Journal of sleep research·2026

Same author

Correspondence: circadian melatonin rhythms in critically ill patients with delirium.

Critical care (London, England)·2026

Same author

Can Morning Light Phase Advance Human Melatonin Rhythms in Less Than 24 h?

Journal of pineal research·2026

Same author

Habitual napping in older adults is accompanied by altered heat-loss rhythms across the circadian cycle and reduced coupling between pre-sleep thermoregulatory dynamics and sleep initiation.

Temperature (Austin, Tex.)·2026

Same author

Afternoon to early evening bright light exposure reduces later melatonin production in adolescents.

Npj biological timing and sleep·2026

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

TAK-375 (Ramelteon) is a melatonin receptor agonist being developed for primary insomnia. Takeda submitted a New Drug Application to the FDA in September 2004 for this potential treatment.

Area of Science:

Pharmacology
Sleep Medicine
Drug Development

Background:

Primary insomnia is a prevalent sleep disorder.
Melatonin receptors (ML1/MT1) play a role in regulating sleep-wake cycles.
Novel therapeutic targets for insomnia are under investigation.

Purpose of the Study:

To evaluate TAK-375 (Ramelteon) as a potential treatment for primary insomnia.
To assess the efficacy and safety of a melatonin receptor agonist.

Main Methods:

TAK-375 (Ramelteon) is a selective melatonin ML1/MT1 receptor agonist.
Development by Takeda.
New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA).

Main Results:

Related Experiment Videos

The submission indicates positive preclinical or clinical data supporting its potential.
Further details on efficacy and safety are expected upon regulatory review.

Conclusions:

TAK-375 (Ramelteon) represents a novel pharmacological approach to primary insomnia.
The NDA submission marks a significant step towards potential clinical availability.